Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2279-2287

  Wiksten, Jan Patrik ^a   Lundin, Johan ^a   Nordling, Stig ^a   Kokkola, Arto ^a   Haglund, Caj ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

bcl 2; Flow cytometry; Gastric cancer; Immunohistochemistry; p21; p53; Prognosis; Syndecan 1; TATI; Tenascin C

Indexed keywords

APROTININ; FORMALDEHYDE; PARAFFIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SYNDECAN 1; TENASCIN; TUMOR MARKER;

ANEUPLOIDY; AREA UNDER THE CURVE; ARTICLE; CELL CYCLE S PHASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURVIVAL; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ANEUPLOIDY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SYNDECAN-1; TENASCIN; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48849107321     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Victorzon M, Nordling S, Haglund C, Lundin J and Roberts PJ: Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 32A(2): 215-220, 1996.
2. Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ and Kim JP: Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis 18(6): 518-525, 2003.
3. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A and Pera M: p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90(1): 206-215, 2004.
4. Al-Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS and Grant C: The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki-67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol 91(4): 243-252, 2005.
5. Kopp R, Diebold J, Dreier I, Cramer C, Glas J, Baretton G and Jauch KW: Prognostic relevance of p53 and bcl-2 immuno- reactivity for early invasive pT1/pT2 gastric carcinomas: indicators for limited gastric resections? Surg Endosc 19(11): 1507-1512, 2005.
6. WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol 4: 94, 2006.
7. Kimura H and Yonemura Y: Flow cytometric analysis of nuclear DNA content in advanced gastric cancer and its relationship with prognosis. Cancer 67(10): 2588-2593, 1991.
8. Russo A, Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Latteri F, Valerio MR, Pantuso G, Morello V, Dardanoni G, Latteri MA, Colucci G, Tomasino RM and Gebbia N: DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study. Cancer 92(2): 294-302, 2001.
9. Setälä LP, Nordling S, Kosma VM, Lipponen PK, Eskelinen MJ, Hollmen SM, Syrjänen KJ and Alhava EM: Comparison of DNA ploidy and S-phase fraction with prognostic factors in gastric cancer. Anal Quant Cytol Histol 19(6): 524-532, 1997.
10. Lee JH, Noh SH, Lee KY, Choi SH and Min JS: DNA ploidy patterns in advanced gastric carcinoma; is it a clinically applicable prognosticator? Hepatogastroenterology 48(42): 1793-1796, 2001.
11. Wiksten J-P, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K and Haglund C: Epithelial and stromal syndecan1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95: 1-6, 2001.
12. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K and Haglund C: Tenascin-C expression correlates with prognosis in gastric cancer. Oncology 64(3): 245-250, 2003.
13. Wiksten JP, Lundin J, Nordling S, Kokkola A, Stenman UH and Haglund C: High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology 46(4): 380-388, 2005.
14. Hermanek P and Sobin LH (eds.): TNM Classification of Malignant Tumours. Fourth edition, 2nd revision. Berlin: Springer-Verlag, pp. 45-48, 1992.
15. Laurén P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
16. Siironen P, Nordling S, Louhimo J, Haapiainen R and Haglund C: Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biol 26(1): 50-56, 2005.
17. Hedley DW, Friedlander ML, Taylor IW, Rugg CA and Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31(11): 1333-1335, 1983.
18. Victorzon M, Roberts PJ, Haglund C, von Boguslawsky K and Nordling S: Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology 53(3): 182-191, 1996.
19. Borrmann R: Geschwülste des Magens und Duodenums. In: Henke F and Lanbarsch O (eds.): Handbuch der Speziellen Pathologischen Anatomie und Histologie. First edition. Berlin: Julius Springer, 1926.
20. Hanley JA and McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148(3): 839-843, 1983.
21. DeLong ER, DeLong DM and Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3): 837-845, 1988.
22. Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T and Sasaki K: Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett 170(2): 183-189, 2001.
23. Fenoglio-Preiser CM, Wang J, Stemmermann GN and Noffsinger A: TP53 and gastric carcinoma: a review. Hum Mutat 21(3): 258-270, 2003.
24. McCabe A, Dolled-Filhart M, Camp RL and Rimm DL: Automated quantitative analysis (AQUA) of in situ protein expression antibody concentration and prognosis. J Natl Cancer Inst 97(24): 1808-1815, 2005.
25. Okuyama T, Maehara Y, Kabashima A, Takahashi I, Kakeji Y and Sugimachi K: Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology 63(4): 353-361, 2002.
26. WAF1/CIP1 in gastric cancer. J Pathol 189(2): 186-193, 1999.
27. waf1/cip1 in gastric carcinoma: lack of interrelationship or correlation with prognosis. Eur J Surg Oncol 26(1): 39-43, 2000.
28. Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. Gynecol Oncol 95(1): 37-45, 2004.
29. WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin Cancer Res 4(11): 2615-2623, 1998.
30. Xie HL, Su Q, He XS, Liang XQ, Zhou JG, Song Y and Li YQ: Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. World J Gastroenterol 10(8): 1125-1131, 2004.
31. Nesi G, Bruno L, Saieva C, Caldini A, Girardi LR, Zanna I, Rapi S, Bechi P, Cortesini C and Palli D: DNA ploidy and S-phase fraction as prognostic factors in surgically resected gastric carcinoma: a 7-year prospective study. Anticancer Res 27(6C): 4435-4441, 2007.
32. Sendler A, Gilbertz KP, Becker I, Mueller J, Berger U, Fink U, van Beuningen D and Siewert JR: Proliferation kinetics and prognosis in gastric cancer after resection. Eur J Cancer 37(13): 1635-1641, 2001.
33. Danesi DT, Spano M, Fabiano A, Altavista P, Pasqualetti P, Toscano MG, Antonini F, Catalane P, Mecozzi A, Picconi A, Daffina A and Cucchiara G: Flow cytometric DNA ploidy, p53, PCNA, and c-erbB-2 protein expressions as predictors of survival in surgically resected gastric cancer patients. Cytometry 42(1): 27-34, 2000.
34. Buyukcelik A, Onur H, Akbulut H, Bulent Y, Ensari A, Utkan G, Onal BS and Icli F: Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori 91(4): 302-308, 2005.
35. Muller W, Schneiders A, Hommel G and Gabbert HE: Prognostic value of bcl-2 expression in gastric cancer. Anticancer Res 18(6B): 4699-4704, 1998.
36. Juuti A, Nordling S, Lundin J, Louhimo J and Haglund C: Syndecan-1 expression-a novel prognostic marker in pancreatic cancer. Oncology 68(2-3): 97-106, 2005.
37. Anttonen A, Kajanti M, Heikkilä P, Jalkanen M and Joensuu H: Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79(3-4): 558-564, 1999.
38. Máthé M, Suba Z, Németh Z, Tâtrai P, Füle T, Borgulya G, Barabâs J and Kovalszky I: Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol 42(5): 493-500, 2006.
39. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E and Doglioni C: High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98(3): 474-483, 2003.
40. Leivonen M, Lundin J, Nordling S, von Boguslawski K and Haglund C: Prognostic value of syndecan-1 expression in breast cancer. Oncology 67(1): 11-18, 2004.
41. Watari J, Saitoh Y, Fujiya M, Shibata N, Tanabe H, Inaba Y, Okamoto K, Maemoto A, Ohta T, Yasuda A, Ayabe T, Ashida T, Yokota K, Obara T and Kohgo Y: Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype. J Gastroenterol 39(2): 104-112, 2004.
42. Lundin M, Nordling S, Lundin J, Isola J, Wiksten JP and Haglund C: Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68(4-6): 306-313, 2005.
43. Zirbes TK, Baldus SE, Moenig SP, Schmilz K, Thiele J, Holscher AH and Dienes HP: Tenascin expression in gastric cancer with special emphasis on the WHO-, Lauren-, and Goseki-classifications. Int J Mol Med 4(1): 39-42, 1999.
44. Ilunga K and Iriyama K: Expression of tenascin in gastric carcinoma: Br J Surg 82(7): 948-951, 1995.
45. Shoji T, Kamiva T, Tsubura A, Hamada Y, Hatano T, Hioki K and Morii S: Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res 55(3): 295-297, 1993.
46. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ and Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38(18): 2362-2370, 2002.
47. Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H and Mikuz G: Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 57(9): 927-931, 2004.
48. Higashiyama M, Monden T, Ogawa M, Matsuura N, Murotani M, Kawasaki Y, Tomita N, Murata A, Shimano T and Mori T: Immunohistochemical study on pancreatic-secretory-trypsin inhibitor (PSTI) in gastric carcinomas. Am J Clin Pathol 93(1): 8-13, 1990.
49. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH and Hsu HC: Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 43(4): 736-744, 2007.